DiaMedica Therapeutics Inc. Common Stock

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DMAC and other ETFs, options, and stocks.

About DMAC

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD).

CEO

Rick John Pauls

CEORick John Pauls

Employees

Employees28

Headquarters

Minneapolis, Minnesota

HeadquartersMinneapolis, Minnesota

Founded

2000

Founded2000

Employees

Employees28

DMAC Key Statistics

Market cap

244.49M

Market cap244.49M

Price-Earnings ratio

-7.31

Price-Earnings ratio-7.31

Dividend yield

—

Dividend yield—

Average volume

378.42K

Average volume378.42K

High today

$4.78

High today$4.78

Low today

$4.45

Low today$4.45

Open price

$4.72

Open price$4.72

Volume

290.03K

Volume290.03K

52 Week high

$6.82

52 Week high$6.82

52 Week low

$3.19

52 Week low$3.19

DMAC News

Seeking Alpha 17h

DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer

Healthcare DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer Aug. 06, 2025 8:48 AM ET DiaMedica Therapeutics Inc. (DMAC) Stock By: Akanksha Kh...

People also own

Based on the portfolios of people who own DMAC. This list is generated using Robinhood data, and it’s not a recommendation.